Bluejay Diagnostics Closes Private Placement, Raises $7.7M Net Proceeds

Bluejay Diagnostics, Inc. announced the closing of a private placement of its securities, raising approximately $7.7 million in net proceeds after fees and expenses. The offering included pre-funded warrants, Series G warrants, and Series H warrants, with a combined price of $2.324 per unit. H.C. Wainwright & Co. served as the exclusive placement agent. The company intends to use the net proceeds to fund matters related to obtaining FDA approval, including clinical studies, as well as for other research and development activities and general working capital needs. Bluejay has also agreed to file a resale registration statement for the securities issued in the placement.